CD38 and colorectal carcinoma: The Morpheus-CRC trial, combining atezolizumab with isatuximab (an anti-CD38 antibody), also showed poor results, with a lack of overall response and shorter overall survival (OS) in the intervention arm (5.1 vs. 10.2 months) [37].